Association of Anticholinergic Burden with Cognitive Impairment and Health Care Utilization Among a Diverse Ambulatory Older Adult Population

Abstract

Study Objective To determine the association between Anticholinergic Cognitive Burden (ACB) score and both cognitive impairment and health care utilization among a diverse ambulatory older adult population. Design Retrospective cohort study. Data Source Medication exposure and other clinical data were extracted from the Regenstrief Medical Record System (RMRS), and cognitive diagnosis was derived from a dementia screening and diagnosis study. Patients A total of 3344 community-dwelling older adults (age 65 yrs and older) who were enrolled in a previously published dementia screening and diagnosis study; of these, 3127 were determined to have no cognitive impairment, and 217 were determined to have cognitive impairment. Measurements and Main Results The study followed a two-phase screening and comprehensive neuropsychiatric examination to determine a cognitive diagnosis, which defined cognitive impairment as dementia or mild cognitive impairment. The ACB scale was used to identify anticholinergics dispensed in the 12 months prior to screening. A total daily ACB score was calculated by using pharmacy dispensing data from RMRS; each anticholinergic was multiplied by 1, 2, or 3 consistent with anticholinergic burden defined by the ACB scale. The sum of all ACB medications was divided by the number of days with any medication dispensed to achieve the total daily ACB score. Health care utilization included visits to inpatient, outpatient, and the emergency department, and it was determined by using visit data from the RMRS. The overall population had a mean age of 71.5 years, 71% were female, and 58% were African American. Each 1-point increase in mean total daily ACB score was associated with increasing risk of cognitive impairment (odds ratio [OR] 1.13, 95% confidence interval [CI] 1.004–1.27, p=0.043). Each 1-point increase in mean total daily ACB score increased the likelihood of inpatient admission (OR 1.11, 95% CI 1.02–1.29, p=0.014) and number of outpatient visits after adjusting for demographic characteristics, number of chronic conditions, and prior visit history (estimate 0.382, standard error [SE] 0.113; p=0.001). The number of visits to the emergency department was also significantly different after similar adjustments (estimate 0.046, SE 0.023, p=0.043). Conclusion Increasing total ACB score was correlated with an increased risk for cognitive impairment and more frequent health care utilization. Future work should study interventions that safely reduce ACB and evaluate the impact on brain health and health care costs.

Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients

“…Although differences exist between findings, the Beers criteria, from the American Geriatrics Society, state that the use of medications that are classified as strong ACs should be avoided in the elderly due to an increased risk of confusion, dry mouth, constipation and other AC effects or toxicity . If alternative treatments with similar efficacy, but no associated AC side effects, are available for use in a particular therapeutic area, it might be possible to reduce the AC burden experienced by the patient …”

Cognitive burden of anticholinergic medications in psychotic disorders

“…Furthermore, the aggregate contribution of numerous medications in treatment regimen can collectively contribute to these effects (Campbell et al, 2016; Gray et al, 2015). Studies of anticholinergic medication effects on cognition in schizophrenia (Baitz et al, 2012; Baker et al, 1983; Brébion et al, 2004; Fayen et al, 1988; Minzenberg et al, 2004; Mori et al, 2002; Perlick et al, 1986; Strauss et al, 1990; Sweeney et al, 1991; Tune et al, 1982; Wojtalik et al, 2012) typically have smaller sample sizes and focus on specific anticholinergic medications (i.e.…”

National Prescribing Trends for High‐Risk Anticholinergic Medications in Older Adults

“…Despite a range of clinical indications, medications with anticholinergic properties pose a number of risks to older adults. These agents are commonly prescribed for allergies, obstructive pulmonary disease, and urge urinary incontinence, but they are associated with risks of serious adverse events, including cognitive impairment, falls, dementia, and death in older adults . This vulnerability to adverse events is due in large part to a variety of aging‐related physiological changes such as poor hepatic and renal function and blood‐brain barrier permeability .…”